Phase II study evaluating the role of exemestane [Aromasine] on clinical and pathologic response rates, and its aromatase activity as treatment in neoadjuvant setting for operable breast cancer patients.

Trial Profile

Phase II study evaluating the role of exemestane [Aromasine] on clinical and pathologic response rates, and its aromatase activity as treatment in neoadjuvant setting for operable breast cancer patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2011

At a glance

  • Drugs Exemestane (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top